top of page
Search

Pharmacovigilance for Natural Health Products in Canada: Regulatory Requirements and Building a Compliant System

Securing a Natural Product Number (NPN) or Homeopathic Medicine Number (DIN-HM) from Health Canada is a major milestone, but it marks the beginning of a product's life cycle, not its end. The day your Natural health product (NHP) becomes available for sale in Canada is the day your post-market safety obligations under the Natural Health Products Regulations (SOR/2003-196) begin to run.

For NHP licensees, these obligations are anchored in Section 24 of the Regulations and operationalized by Health Canada's Natural and Non-prescription Health Products Directorate (NNHPD), with detailed guidance issued by the Marketed Health Products Directorate (MHPD). Together they create a continuous duty: identifying, evaluating, and reporting adverse reactions associated with your product throughout its entire commercial life.

Our thesis is straightforward. A robust pharmacovigilance (PV) or product safety surveillance system is not a regulatory burden, it is a strategic asset. A well-designed product safety surveillance system protects your site licence under Health Canada inspections, catches safety signals before they become recalls, builds consumer trust, and creates a scalable foundation for international expansion. This article reviews the key Canadian regulatory requirements for NHP product safety surveillance and provides practical guidance on building a system that meets them.

1. The Canadian Regulatory Framework for NHPs

Natural Health Products are a distinct regulated category under Canadian law. The Natural Health Products Regulations define them to include vitamins and minerals, herbal remedies, traditional medicines (including Traditional Chinese and Ayurvedic medicines), homeopathic medicines, and probiotics, among other categories, where they meet specified compositional and indication criteria. NHPs are regulated as a sub-category of "drug" under the Food and Drugs Act, but with a separate regulatory regime tailored to their generally lower-risk profile.

Pre-market requirements

  • Product licensing: every NHP requires a Natural Product Number (NPN) or a Homeopathic Medicine Number (DIN-HM), supported by evidence of safety, efficacy, and quality.

  • Site licensing and Good Manufacturing Practices: every manufacturing, packaging, labelling, or importing site requires a site licence and must comply with Part 3 of the Regulations, recently updated through GUI-0158 Version 4.0, effective March 4, 2026.

Post-Market obligations

Section 24 of the Natural Health Products Regulations is the heart of the post-market requirements, elaborated through the Reporting Adverse Reactions to Marketed Health Products – Guidance Document for Industry (2018, as modified by a Notice to Industry dated February 19, 2026) and the Preparing and Submitting Summary Reports guidance (2018, currently under revision following a public consultation that closed in December 2025).

An additional regulatory development warrants attention. With the Royal Assent of Bill C-47 on June 22, 2023, Vanessa's Law (the Protecting Canadians from Unsafe Drugs Act) was extended to NHPs. Health Canada can now order mandatory recalls of unsafe NHPs and impose fines of up to $5 million per offence. This has significantly increased the stakes of a post-market safety failure.

2. Key Adverse Reaction Reporting Requirements

Serious vs non-serious adverse drug reactions

Understanding the distinction between serious and non-serious adverse reactions is critical for managing compliance. According to the Natural Health Product Regulations, a serious adverse reaction is a noxious response to a Natural Health Product that requires inpatient hospitalization, causes congenital malformation, results in persistent or significant disability, is life-threatening, or results in death. Any adverse reaction that does not meet these criteria is considered non-serious.

Section 24 establishes the two pillars of NHP pharmacovigilance: expedited case reporting and annual summary reporting.

Expedited 15-Day Reporting

Under Section 24(1), every licensee must submit to Health Canada, within 15 calendar days of becoming aware of the reaction, (a) a case report for each serious adverse reaction occurring inside Canada, and (b) a case report for each serious unexpected adverse reaction occurring inside or outside Canada.

The 15-day clock starts on "day 0", the day the licensee, or a contractor acting on its behalf, first has all four minimum criteria for a valid case: an identifiable reporter, an identifiable patient, a suspect product, and an adverse reaction. If a call centre or third-party PV provider receives the case first, day 0 starts when they receive it, not when the licensee is internally notified. This is among the most common misunderstandings observed in Health Canada inspections.

Reporting Criteria

Reportability turns on three variables: seriousness, expectedness, and geography. The matrix below, the single most important reference for any NHP safety stakeholder, summarizes how the three combine.

Type of Adverse Reaction

Domestic — Expedited?

Foreign — Expedited?

Include in ASR?

Serious Expected

YES (15 days)

NO

YES

Serious Unexpected

YES (15 days)

YES (15 days)

YES

Non-Serious Expected

NO

NO

Domestic only

Non-Serious Unexpected

NO

NO

Domestic only

The Canada Vigilance Program

All licensee case reports flow into the Canada Vigilance database. Voluntary reports from consumers and healthcare professionals also populate this database, which licensees should consult to support signal detection.


Annual Summary Reports, Signal Detection, and Record Retention

Under Section 24(2), every licensee must prepare and maintain, every twelve months, a summary report containing a concise and critical analysis of all adverse reactions occurring in Canada and all serious unexpected reactions worldwide over the preceding twelve months. The ASR is product-specific and must be maintained from the date of first sale in Canada until the expiry date of the last lot sold. It need not be submitted routinely, but the Minister may request it (or an interim report) at any time, in which case it must be provided within 30 days.

Beyond individual case reporting, Health Canada expects licensees to monitor cumulative case data for emerging safety signals — patterns of reactions that may indicate a previously unrecognized risk. Records of case reports and summary reports should be retained for a minimum of 25 years per Health Canada guidance, and be retrievable within 72 hours.


Figure 1: The adverse reaction reporting workflow

3. Building a Compliant Product Safety Surveillance System

A compliance-ready NHP pharmacovigilance system has several interlocking elements. Each is scalable from small single-product licensees to multinational portfolios.

3.1. Governance and Organization

Appoint a qualified responsible person typically a designated Qualified Person for Pharmacovigilance or equivalent, with the authority and medical judgement to oversee the system. Document senior management oversight (a PV Steering Committee or equivalent works well). Assign roles in writing for case intake, processing, submission, ASR preparation, signal detection, and quality oversight.

3.2. System infrastructure

Implement a safety database appropriate to your product volume and complexity. Small licensees with low case volume can operate effectively with a validated spreadsheet or simple case management tool; larger licensees — or those exporting to multiple jurisdictions should adopt a dedicated pharmacovigilance database supporting ICH E2B(R2) electronic submission. Validation is essential, whichever route is chosen; however, a safety database is always ideal. Backup, change control, audit trails, and user access controls are non-negotiable.


3.3 Processes and Procedures

Document SOPs covering, at minimum:

  • Adverse reaction intake from all sources — consumers, healthcare professionals, literature, regulatory authorities, internet sources, and contracted parties;

  • Case processing, medical assessment, MedDRA coding, and causality evaluation;

  • Expedited (15-day) reporting and ASR workflows;

  • Signal detection methodology and benefit-risk evaluation;

Quality control at every step.


3.4. Training and Quality Management

Every person with PV responsibilities should be trained on the SOPs relevant to their role, with training completion documented. A periodic self-audit program identifies gaps before Health Canada does. A deviation and CAPA (Corrective and Preventive Action) system captures and resolves quality failures.


3.5. Integration with other Quality Systems

Pharmacovigilance does not operate in isolation. Connect it to Good Manufacturing Practices (lot and batch tracking, complaint investigation), Quality Assurance (deviation and change control, product complaints), recall procedures (a safety signal may trigger a recall decision), and Regulatory Affairs (label changes flowing from new safety information).


3.6. Documentation and Retention

Maintain a written description of your PV system — a Pharmacovigilance System Master File (PSMF), or equivalent. Document every case file, every follow-up attempt, and every ASR. Retain records for a minimum of 25 years per Health Canada guidance, with retrieval possible within 72 hours.


Practical Tips-Scaling for Small and Larger Manufacturers

Small NHP companies often run lean PV systems with one or two staff plus contracted services — this is acceptable, but it places a premium on contractor agreements. Every contractor performing PV activities should be covered by a written Safety Data Exchange Agreement (SDEA) defining day-0 timelines, data transfer mechanisms, audit rights, and termination procedures. The most common compliance pitfalls observed in inspections, across all company sizes, are: mis-calculation of day 0; downgrading of seriousness contrary to the reporter's assessment; absent or outdated SDEAs; incomplete ASRs; inadequate record retention; and inconsistent literature monitoring.


4. Benefits, and the Business Case for Proactive Vigilance

Compliance is not the only return on a well-built PV system. A robust system delivers four distinct categories of business value.

Public Health Protection

The most important consequence of a well-functioning PV system is the early detection of safety signals that protect consumers from emerging risks. This is the ethical core of the obligation, and the foundation on which every other business benefit rests.

Audit readiness

Health Canada conducts Good Pharmacovigilance Practices (GVP) inspections on a risk-based schedule. A licensee whose system is built to current guidance, with documented SOPs, training records, and case files accessible within 72 hours, enters those inspections with confidence. The alternative, reactive remediation under inspector scrutiny, is materially more costly.

Brand Equity

Safety signals caught early are managed quietly. Safety signals missed become recalls. Since June 2023, those recalls may be ordered by Health Canada under Vanessa's Law, with corresponding media coverage and consumer trust implications. A strong PV system is, in effect, brand insurance.

The Export Advantage

This is the strategic upside most often overlooked. A PV system built to Health Canada's standards, which are harmonized with international standards, already satisfies the baseline pharmacovigilance requirements of major international markets, including the European Union (EU Good Vigilance Practices), the United Kingdom, Australia (TGA), and many Asian markets. NHP companies that build a Canadian-compliant PV system are positioning themselves for global expansion without rebuilding the foundation.


Conclusion and Next Steps

A compliant NHP pharmacovigilance system rests on three foundations: standardized SOPs, continuously trained personnel, and strict adherence to the processes. It is feasible to build at any company size, scalable across product portfolios, and when designed thoughtfully, a strategic asset rather than a regulatory burden.


How VigiQuest Analytics Can Help

Whether you are scaling up from a startup with a single product or running a multinational with a complex portfolio, VigiQuest Analytics can assess your current pharmacovigilance posture and recommend the right path forward. Our pharmacovigilance and regulatory affairs practice supports NHP licensees with:

  •  Compliance gap analyses and GVP inspection readiness assessments

  • SOP development, Safety Data Exchange Agreement review, and PV staff training

  • End-to-end adverse reaction case management and Annual Summary Report preparation

  • Signal detection, benefit-risk evaluation, and Health Canada response support

  • Strategic advice on the evolving NHP regulatory framework


Resources

 
 
 

Recent Posts

See All

Comments

bottom of page